Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)

China · Delayed Price · Currency is CNY

74.50

+10.40 (16.22%)

At close: Feb 27, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Preparations	186.79M	-	297.92M	465.37M	-
Preparations Growth	-	-	-35.98%	-	-
Pharmaceutical Distribution and Others	38.00M	-	103.13M	64.24M	-
Pharmaceutical Distribution and Others Growth	-	-	60.53%	-	-
Active Pharmaceutical Ingredient (api)	10.32M	-	-	-	-
Others	5.51M	-	-	-	31.50M
Others Growth	-	-	-	-	7602.45%
Sodium Acetate Ringer's Injection	-	-	-	-	458.67M
Sodium Acetate Ringer's Injection Growth	-	-	-	-	2.15%
Total	240.63M	-	401.05M	529.62M	490.16M
Total Growth	-	-	-24.28%	8.05%	9.06%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	240.63M	334.30M	401.05M	529.62M	490.16M
China Growth	-28.02%	-16.64%	-24.28%	8.05%	9.06%
Total	240.63M	334.30M	401.05M	529.62M	490.16M
Total Growth	-28.02%	-16.64%	-24.28%	8.05%	9.06%

Source: S&P Global Market Intelligence.